ACHILLES THERAPEUTICS PLC ADS EACH REPR 1 SHARE SPON.
Achilles Therapeutics is a clinical-stage biopharmaceutical company based in the United Kingdom that is developing personalized T cell therapies for the treatment of cancer. The company was founded in 2016 and is listed on the NASDAQ under the ticker symbol "ACHL."
Achilles Therapeutics is developing a novel approach to cancer immunotherapy that involves targeting neoantigens, which are unique peptides found on the surface of cancer cells that are not present on healthy cells. By targeting these neoantigens, Achilles Therapeutics aims to develop personalized T cell therapies that can selectively destroy cancer cells while leaving healthy cells unharmed.
The company's lead product candidate, ATLAS-001, is a personalized T cell therapy for the treatment of solid tumors. ATLAS-001 is derived from the patient's own T cells, which are isolated and genetically engineered to recognize and target neoantigens found on the surface of the patient's cancer cells. The therapy is designed to be given as a single infusion and has shown promising results in early-stage clinical trials.
Achilles Therapeutics is also developing a pipeline of product candidates for the treatment of different types of cancer, including melanoma, lung cancer, and pancreatic cancer. The company's approach to cancer immunotherapy has the potential to revolutionize cancer treatment by providing patients with personalized therapies that are tailored to their specific cancer.
In addition to its product pipeline, Achilles Therapeutics has also developed a proprietary platform for the identification of neoantigens. The platform uses advanced bioinformatics tools and machine learning algorithms to analyze patient tumors and identify the unique neoantigens that are present. This approach enables the company to develop personalized therapies that are specific to each patient's cancer.
The global cancer immunotherapy market is expected to reach $126.9 billion by 2025, according to a report by Grand View Research. As the demand for personalized cancer therapies continues to grow, Achilles Therapeutics is well-positioned to capitalize on the opportunities presented by the expanding market.
Achilles Therapeutics is a clinical-stage biopharmaceutical company that is developing personalized T cell therapies for the treatment of cancer. The company's approach to cancer immunotherapy involves targeting neoantigens found on the surface of cancer cells, which has the potential to provide patients with personalized therapies that are tailored to their specific cancer. With a pipeline of product candidates and a proprietary platform for the identification of neoantigens, Achilles Therapeutics is well-positioned to capitalize on the opportunities presented by the expanding cancer immunotherapy market.